Keytrida plus Lenvima improved survival and duration of response in patients with advanced hepatocellular carcinoma. Adding Keytruda (pembrolizumab) to Lenvima (lenvatinib) led to better duration of ...
Among the 27 responding patients, 81% had a duration of response (DOR) of six months or longer, and 37% had a DOR of 12 months or longer. In June 2020, KEYTRUDA was granted its first indication in ...
After AstraZeneca’s Imfinzi last year claimed new territory in the biliary tract cancer space, Merck’s Keytruda has hit the scene with an FDA nod to match its rival. The approval in locally advanced ...
Olomorasib plus Keytruda was proven to be safe and well tolerated for patients with KRAS G12C-mutant non-small cell lung cancer. The novel drug, olomorasib, when given with Keytruda (pembrolizumab), ...
Morning Overview on MSN
An mRNA vaccine paired with Keytruda cut melanoma recurrence by nearly 50% over five years in a landmark NYU-led trial
Patients with high-risk melanoma who received a personalized mRNA cancer vaccine alongside pembrolizumab after surgery saw ...
Imfinzi (durvalumab) and Keytruda (pembrolizumab) are prescription drugs used to treat various forms of cancer. Both drugs are administered as intravenous (IV) infusion into a vein. Your dosage for ...
KEYTRUDA in combination with Inlyta (axitinib) for the first-line treatment of patients with radically unresectable or metastatic RCC; KEYTRUDA in combination with chemotherapy for the first-line ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results